Acrivon Therapeutics Inc. announced significant progress in its clinical pipeline, including updates from the ongoing Phase 2b trial of ACR-368 in endometrial cancer. Interim electronic data capture from the study showed an overall response rate of 39% among OncoSignature-positive subjects, with a 44% response rate in those with two or fewer prior lines of therapy. In the subset of serous endometrial cancer patients with two or fewer prior treatments, a confirmed overall response rate of 52% was observed, and 67% in biomarker-positive subjects. The company also reported initial clinical data from the ACR-2316 Phase 1 study and announced the nomination of ACR-6840, a potential first-in-class oral CDK11 inhibitor, as its next preclinical development candidate. Results from the ACR-368 trial have already been presented, and the company has submitted a Phase 3 study protocol for ACR-368 in combination with anti-PD-1 therapy to the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622217-en) on January 08, 2026, and is solely responsible for the information contained therein.